Investors / Palo Santo
Palo Santo
Venture capital
Palo Santo is a neuroscience fund that invests in companies developing therapeutics and technologies for mental health. Its portfolio spans neurological therapeutics, next-generation psychedelic therapies, and brain health technologies.
Invests inHealthcare & Biotech
In its own wordsneurosciencemental healthpsychedelicscns therapeuticsbiotechneurotechnology
Your fit with Palo Santo
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsPalo Santo lists 25 checked portfolio companies on its own site. Its largest themes are Healthcare & Biotech (85%), Industrial & Manufacturing (4%) and Mobility & Logistics (4%). 73% of its companies are based in United States. It invests most often alongside Negev Capital, Noetic Fund and Neo Kuma Ventures.
No funding round on record names Palo Santo yet, so the figures come from its portfolio page.
Round figures show recent activity, not Palo Santo's whole history. Rounds on record name 0 companies; its own site lists 25. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 60th | 25 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 94th | 85% in its largest sector |
| Reach | 78th | 5 countries |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers2496%
- No longer answers00%
- Points to another company14%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 85% | 15% |
| Industrial & Manufacturing | 4% | 7% |
| Mobility & Logistics | 4% | 1% |
| AI & Machine Learning | 4% | 18% |
| Real Estate & Construction | 4% | 3% |
Co-investor network
who it backs companies with, and who they back togetherCompare Palo Santo head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Portfolio
25 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| 2A Biosciences is developing precision agonists to restore neural circuitry and immune balance | Healthcare & Biotech | Portfolio page | ||
| AtaiBeckley develops mental health treatments | Healthcare & Biotech | Portfolio page | ||
| Beacon Biosignals uses AI-powered technology to accelerate drug development and power home sleep testing diagnostics | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Blackbox Bio provides automated in vivo behavioral analysis for research using machine learning | Healthcare & Biotech | Portfolio page | ||
| BRC Therapeutics is working to develop safe, non-addictive medicines to address pain and other conditions. | Healthcare & Biotech | Portfolio page | ||
| Bright Minds develops drugs for mental health and neurology | Healthcare & Biotech | Portfolio page | ||
| Xylo provides an AI-powered workspace to help planning teams with administrative tasks and decision-making | AI & Machine LearningReal Estate & Construction | Portfolio page | ||
| Helus Pharma develops novel serotonergic agonists for the treatment of mental health conditions | Healthcare & Biotech | Portfolio page | ||
| Delix Therapeutics is developing novel therapeutics to address brain health challenges | Healthcare & Biotech | Portfolio page | ||
| Diamond Therapeutics is developing safe and approved therapies for neuropsychiatric conditions, starting with sub-perceptual psilocybin-based medicines | Healthcare & Biotech | Portfolio page | ||
| Fauna Bio is an AI-driven drug discovery company that leverages data from 100 million years of evolved disease resistance in mammals to create new drugs for humans. | Healthcare & Biotech | Portfolio page | ||
| Fluence provides water and wastewater treatment solutions | Industrial & ManufacturingMobility & Logistics | Portfolio page | ||
| Gilgamesh Pharma develops innovative new chemical entities to transform the treatment paradigm of psychiatric disease | Healthcare & Biotech | Portfolio page | ||
| Journey-Clinical provides ketamine-assisted psychotherapy and other psychedelic treatments for various mental health conditions. | Healthcare & Biotech | Portfolio page | ||
| Kadence Bio is a clinical-stage life sciences company developing novel therapeutics to address areas of significant unmet need in sexual and mental health. | Healthcare & Biotech | Portfolio page | ||
| Ksana Health digitally transforms behavioral healthcare through technology and provides a platform for personalized behavioral insight and intervention. | Healthcare & Biotech | Portfolio page | ||
| MycoMedica develops psilocybin-based treatments for mental health and neurodegenerative disorders | Healthcare & Biotech | Portfolio page | ||
| The company empowers clinicians to embed leading therapy innovations to improve clinical and commercial outcomes | Healthcare & Biotech | Portfolio page | ||
| Pangea Bio develops novel neuroplastic therapeutics to treat central nervous system disorders | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- palosanto.vc
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Companies checked
- 25
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Palo Santo's profile as data
Pull Palo Santo's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/palosanto.vc
# also
GET /v1/firms/palosanto.vc/portfolio
GET /v1/firms/palosanto.vc/coinvestors
GET /v1/firms/palosanto.vc/news